IFB Health Economic Evaluations 2027
Introduction:
IFB Health Economic Evaluations 2025:
A unique 2-day course with theory, practical exercises and workshops on state-of-the art cases.
Participants interact personally with leading academics and authorities.
In the current health care context, efficacy and safety of medicines are no longer sufficient for successful market access.
Innovative treatments, medical devices and diagnostics need to show added therapeutical value and provide “value for money”.
This IFB course gives thorough insights in the concepts and principles of health economic evaluations and health technology assessment (HTA) with a focus on the Belgian context and including the latest updates on the EU Joint Clinical Assessment (JCA).
These evaluations have become key requirements in the development and reimbursement of new treatments, since authorities allocate available budgets to those treatments that provide the most health gain for each Euro invested.
The course also focuses on new, hot issues, such as Real World Data and Indirect Treatment Comparisons.
Participants get the latest updates on the Roadmap towards the reform of the reimbursement process and on the Belgian health economic guidelines.
This IFB course gives a practical view on the way Health Economic Evaluations are built in the context of reimbursement submissions and provides basic technical insights which allows you to interact more efficiently with Health Economic experts and authorities.
Timing:
Preliminary dates 2027: February 2-3, 2027 (Thursday & Friday from 9.00-17.00h)
Detailed program:
2/02/2027| 8.30h | Reception with coffee |
| 9.00-12.30h |
Introduction to health economic evaluations - Lieven Annemans
|
| 13.30-17.00h |
Methods for health economic evaluations - Lieven Annemans
|
3/2/2027
| 8.30h | Reception with coffee |
| 9.00-12.30h |
Step by step exploration of a health economic analysis - Karen Moeremans Participants receive a fictive health economic model in MS Excel.
Participants are requested to bring their laptop for exercises and exploration of the model in MS Excel. |
| 13.30- 15.30h |
Belgian guidelines for health economic evaluations and reporting - Francis Arickx (RIZIV) - presented with a focus on:
|
| 15.45-17.00h |
Health economic evaluations and HTA in decision making on reimbursement: challenges and trends - Lieven Annemans
|
Your speakers / Faculty members: for more details see under
- Prof. Dr. Lieven Annemans - Professor Health Economics UGent
- Francis Arickx: Head Pharmaceutical Policy RIZIV/INAMI and chair HTA consortium
- Dr. Karen Moeremans: Managing partner and health economist CHESS
Lieven Annemans: Lieven Annemans, PhD, MMan, MSc, Full Professor of health economics, Ghent University and consultant at INFOHECO. He is Past President of ISPOR, the International Society for PharmacoEconomics and Outcomes Research, and ex-advisor to the Minister of Social Affairs. He has > 25 years of experience in health-economic evaluations of pharmaceutical drugs, vaccines, medical devices, diagnostics, and preventive health actions in various medical areas. His main research interests are epidemiological models, Health Technology Assessment (HTA), retrospective/prospective health-economic evaluations, and physician payment systems. He has published > 300 papers in peer-reviewed journals and has given hundreds of lectures and trainings on health-economic evaluations and HTA.
He is author of the book “Health economics for non-economists: an introduction to the concepts, methods and pitfalls of health economic evaluations” (Pelckmans Pro 2018). His other books "De prijs van uw gezondheid"(2014) and "Je geld of je leven in de gezondheidszorg" (2017) show the challenges of the Belgian Health system and proposed solutions.
Francis Arickx: Head Pharmaceutical Policy RIZIV/INAMI and chair HTA consortium.Francis Arickx is the Head of the directorate Reimbursement of Medicines and Pharmaceutical Policy within the Health Care Department at the National Institute for Health and Disability Insurance (NIHDI RIZIV/INAMI) in Belgium where he manages the departments responsible for administrative and scientific assessment and appraisal of reimbursement claims for medicines, orphan drugs, medical nutrition,… Francis Arickx is the former secretary general for the Commission for Reimbursement of Medicines and acts as representative/expert for the Institute and Belgium on a number of national and European platforms (NM CAPR, MEDEV, MoCA,..). He is one of the country coordinators for the BeNeLuxA Initiative (www.beneluxa.org). Francis graduated in pharmaceutical sciences from the University of Ghent, Belgium and teaches ‘Health Policy’ in the Pharmaceutical Sciences Department at the University of Antwerp. Francis Arickx studied pharmaceutical sciences at the University of Ghent, where he graduated in 1989.
Karen Moeremans: Managing partner and health economist at CHESS. Karen graduated as MD in 1993. Karen worked for several years in pharmaceutical industry as a CRA and medical advisor. Since 1998 Karen has been conducting and managing health economic projects, first as health scientist at HEDM, later as consultant, senior consultant and director of Health Economics and Outcomes Research (HEOR) at IMS Health Consulting. In 2013, Karen joined CHESS, a small-scale company striving to provide high quality-driven consulting services in health economic simulations and strategies. During these 20 years in health economics, Karen’s work has involved the management, conduct, supervision and quality assurance of HEOR projects, both at a national and international level. She gained experience in health economic evaluations in a wide range of disease areas such as oncology, hematological oncology, gynaecology, ophthalmology, dermatology, infectious diseases, psychiatric diseases, neurology, vaccines... . Her broad experience encompasses health economic modelling, cost-effectiveness and cost-utility evaluations, cost of illness studies, budget impact analysis… At CHESS Karen is responsible for the conduct or the quality assurance of health economic projects which include performing cost-effectiveness and budget impact analyses for reimbursement dossiers, developing global economic models, performing technical model validations, …
Moderator: Dirk Broeckx (IFB)
Where?
This 2 day training will take place in Brussels (Grand-Bigard/ Groot-Bijgaarden) - Salons Waerboom and is non-residential.
Language?
English.
Price?
• The 2-day training::
o Seminar fee: 1.695 € (excl. VAT)
o Catering for 2 days ( including lunches, breaks,…): 205 € (excl. Vat)
Price reductions?
• IFB members receive a 5 % discount
• For non-profit organizations we offer a 50% discount.
Small and medium enterprises (SMEs) can profit from the KMO portefeuille (www.kmo-portefeuille.be or call 1700 for more information).
- The authorisation number is DV.O104106. The number of formation hours during this 2 X 8 h. Check this on the website www.kmo-portefeuille.be or call nr 1700.(Innovation / company strategy)
In order to register for this course, you need to login or create a new account.
Click here to login or register
